NasdaqCM - Nasdaq Real Time Price USD

Nuwellis, Inc. (NUWE)

0.2890

+0.0369

(+14.64%)

At close: April 25 at 4:00 PM EDT

0.2800

-0.01

(-3.11%)

After hours: April 25 at 7:50 PM EDT

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

MINNEAPOLIS, April 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that Detroit, Michigan-based health system, Henry Ford Health, has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company’s Aquadex SmartFlow system as part of Nuwellis’ pivotal REVERSE-HF clinical study. “We are excited to study the impact of Aquadex SmartFlow therapy on our heart failure patients who are suffering from severe fluid overload,” s

GlobeNewswire 16 days ago

NUWE
+14.64%
NUWEW
Nuwellis Full Year 2023 Earnings: EPS Beats Expectations

Nuwellis ( NASDAQ:NUWE ) Full Year 2023 Results Key Financial Results Revenue: US$8.86m (up 3.8% from FY 2022). Net...

Simply Wall St. last month

NUWE
+14.64%
NUWEW
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial intelligence and machine learning-based model show that lifestyle and clinical factors can be strong predictors of heart failure events MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid over

GlobeNewswire last month

NUWE
+14.64%
NUWEW
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital AccountsMINNEAPOLIS, March 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenu

GlobeNewswire last month

NUWE
+14.64%
NUWEW
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the

GlobeNewswire last month

NUWE
+14.64%
NUWEW
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribution partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), has received Humanitarian Device Exemption (HDE) from the U.S. Food and Drug Administration (FDA) for Quelimmune™, its pediatric Selective Cytopheretic Device. Quelimmune provides a new therapy option for children wei

GlobeNewswire 2 months ago

ICU

ICUCW

NUWE
+14.64%
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to two individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved

GlobeNewswire 2 months ago

NUWE
+14.64%
NUWEW
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

Nuwellis to share three presentations highlighting the company’s Aquadex SmartFlow systemMINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its planned activities at the upcoming Technology and Heart Failure Therapeutics conference (THT 2024), which is produced by the Cardiovascular Research Foundation (CRF), taking place March 4-6, in Boston. Nuwellis will exh

GlobeNewswire 2 months ago

NUWE
+14.64%
NUWEW
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don’t respond to diureticsMINNEAPOLIS, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the publication of new data demonstrating the potential value of the Aquadex SmartFlow® system’s aquapheresis therapy when treating patients with fluid ov

GlobeNewswire 2 months ago

NUWE
+14.64%
NUWEW
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologiesMINNEAPOLIS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its specialty peripheral dual lumen extended length catheter (dELC). The addition of a new 12 cm catheter prov

GlobeNewswire 3 months ago

NUWE
+14.64%
NUWEW
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

The data demonstrate that the hematocrit sensor within the Nuwellis Aquadex® system offers unique advantages for fluid overloaded small patientsMINNEAPOLIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- New real-world data demonstrate that pediatric patients with fluid overload respond well to Aquadex® ultrafiltration therapy with continuous hematocrit monitoring, announced Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload. The public

GlobeNewswire 4 months ago

NUWE
+14.64%
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

MINNEAPOLIS, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023. Revenue of $2.4 million for the third quarter 2023, increased 16% over the prior quarter and increased 17% over the prior-year period.Therapy utilization, or the number of circuits per placed console, increased 26% over the prior year, reflectin

GlobeNewswire 5 months ago

NUWE
+14.64%
Nuwellis Announces Board of Directors Transition

Nuwellis Announces Appointment of Dr. Archelle Georgiou, MD and Dave McDonald to its Board of DirectorsMINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. “With decades of experience and leadership in their respective fields, we welcome Dave and Arc

GlobeNewswire 5 months ago

NUWE
+14.64%
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device

MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its strategic partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its pediatric Selective Cytopheretic Device (SCD-PED). The SCD-PED will provide a new therapy option for children weighing 10 kilograms o

GlobeNewswire 5 months ago

NUWE
+14.64%
ICU
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company’s financial results and provide a general business overview. To access the live webcast, please visit t

GlobeNewswire 6 months ago

NUWE
+14.64%
Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

MINNEAPOLIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 150,000 units (the “Units”), with each Unit consisting of one share of the Company’s Series J Convertible Redeemable Preferred Stock, par value $0.0001 per share, with a liquidation preference of $25.00 per share (the “Series

GlobeNewswire 6 months ago

NUWE
+14.64%
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

MINNEAPOLIS, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 150,000 units (the “Units”), with each Unit consisting of one share of the Company’s Series J Convertible Redeemable Preferred Stock, par value $0.0001 per share, with a liquidation preference of $25.00 per share (the “Series J Convertible Preferre

GlobeNewswire 6 months ago

NUWE
+14.64%
Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

MINNEAPOLIS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that its distribution partner, SeaStar Medical (SeaStar), received correspondence from the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) indicating that the Agency considers SeaStar’s Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) to be appro

GlobeNewswire 6 months ago

NUWE
+14.64%
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase

MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief Medical Officer Dr. John Jefferies, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 12:00 pm ET. To access the live webcas

GlobeNewswire 7 months ago

NUWE
+14.64%
Nuwellis, Inc. Announces Second Quarter 2023 Financial Results

MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2023. Revenue of $2.1 million for the second quarter 2023, representing a 14% increase over the prior quarter and a 6% decrease over the prior-year period.Utilization, or the number of circuits per console, increased 14% over the same period last year, re

GlobeNewswire 8 months ago

NUWE
+14.64%

Performance Overview

Return	NUWE	S&P 500
YTD	-50.17%	+5.84%
1-Year	-93.74%	+22.03%
3-Year	-99.94%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nuwellis, Inc. (NUWE)

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Nuwellis Full Year 2023 Earnings: EPS Beats Expectations

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

Nuwellis Announces Board of Directors Transition

Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device

Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase

Nuwellis, Inc. Announces Second Quarter 2023 Financial Results

Performance Overview